News

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
Is Novo Nordisk (NVO) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...
yr.no3h
Novo Mesto
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...